CSL830

PreclinicalBiologic

CSL Behring

CSL830 is one of 13 biologic programs targeting Hereditary Angioedema. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hereditary AngioedemaActive, not recruiting

Hereditary AngioedemaPreclinical

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Hereditary Angioedema

#DrugCompanyPhaseTrials

Crestor

Neoral

Lanoxin

Andembry

1 5

Dawnzera (autoinjector)

Ionis Pharmaceuticals

Phase 3

5 6

Orladeyo

BBioCryst Pharmaceuticals

Phase 3

1 7

Deucrictibant

PPharvaris Netherlands B.V.

Phase 3

4 8

KVD900

KKalVista Pharmaceuticals, Ltd.

Phase 3

5 9

ADX-324

AADARx Pharmaceuticals, Inc.

Phase 2

2 10

Heparin Sodium

BBaxter Healthcare Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics1 trial

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

Completed· CSL Behring logo

CSL Behring·Phase 1·NCT01760343·16 enrolled

Hereditary Angioedema1 trial

Expanded Access for Hereditary Angioedema (HAE)

Approved for marketing·JJoshua S. Jacobs, MD··NCT03177005

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CSL830. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CSL830 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CSL830. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CSL Behring

CSL830

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics1 trial

Hereditary Angioedema1 trial

References

Drug Info

Quick Facts

Related News